362 related articles for article (PubMed ID: 28819868)
41. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?
Kiran RP; Kirat HT; Burgess AN; Nisar PJ; Kalady MF; Lavery IC
Ann Surg Oncol; 2012 Apr; 19(4):1206-12. PubMed ID: 21935748
[TBL] [Abstract][Full Text] [Related]
42. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
43. Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer: Is It Really More Dangerous?
Habr-Gama A; São Julião GP; Vailati BB; Fernandez LM; Ortega CD; Figueiredo N; Gama-Rodrigues J; Perez RO
Dis Colon Rectum; 2019 Jun; 62(6):675-683. PubMed ID: 30870223
[TBL] [Abstract][Full Text] [Related]
44. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
45. Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy?
Park SY; Chang HJ; Kim DY; Jung KH; Kim SY; Park JW; Oh JH; Lim SB; Choi HS; Jeong SY
Histopathology; 2011 Oct; 59(4):650-9. PubMed ID: 22014046
[TBL] [Abstract][Full Text] [Related]
46. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
[TBL] [Abstract][Full Text] [Related]
47. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
Tranchart H; Lefèvre JH; Svrcek M; Flejou JF; Tiret E; Parc Y
Ann Surg Oncol; 2013 May; 20(5):1551-9. PubMed ID: 23188545
[TBL] [Abstract][Full Text] [Related]
48. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
49. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.
Shia J; McManus M; Guillem JG; Leibold T; Zhou Q; Tang LH; Riedel ER; Weiser MR; Paty PB; Temple LK; Nash G; Kolosov K; Minsky BD; Wong WD; Klimstra DS
Am J Surg Pathol; 2011 Jan; 35(1):127-34. PubMed ID: 21164296
[TBL] [Abstract][Full Text] [Related]
50. A Nomogram to Predict Lymph Node Positivity Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Newton AD; Li J; Jeganathan AN; Mahmoud NN; Epstein AJ; Paulson EC
Dis Colon Rectum; 2016 Aug; 59(8):710-7. PubMed ID: 27384088
[TBL] [Abstract][Full Text] [Related]
51. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
Guillem JG; Ruby JA; Leibold T; Akhurst TJ; Yeung HW; Gollub MJ; Ginsberg MS; Shia J; Suriawinata AA; Riedel ER; Mazumdar M; Saltz LB; Minsky BD; Nash GM; Paty PB; Temple LK; Weiser MR; Larson SM
Ann Surg; 2013 Aug; 258(2):289-95. PubMed ID: 23187748
[TBL] [Abstract][Full Text] [Related]
52. Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study.
Liao YT; Lin YL; Huang J; Hung JS; Lin BR
Int J Colorectal Dis; 2021 Mar; 36(3):509-516. PubMed ID: 33128083
[TBL] [Abstract][Full Text] [Related]
53. Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer.
Beard BW; Rettig RL; Ryoo JJ; Parker RA; McLemore EC; Attaluri V
J Am Coll Surg; 2020 Dec; 231(6):681-692. PubMed ID: 33121903
[TBL] [Abstract][Full Text] [Related]
54. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation.
Tawfik B; Mokdad AA; Patel PM; Li HC; Huerta S
Anticancer Drugs; 2016 Oct; 27(9):879-83. PubMed ID: 27434664
[TBL] [Abstract][Full Text] [Related]
55. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
56. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
[TBL] [Abstract][Full Text] [Related]
57. High nodal positivity rates even in good clinical responders after chemoradiation of rectal cancer: is organ preservation feasible?
Vallam KC; Engineer R; Desouza A; Patil P; Saklani A
Colorectal Dis; 2016 Oct; 18(10):976-982. PubMed ID: 26362820
[TBL] [Abstract][Full Text] [Related]
58. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.
Bibault JE; Giraud P; Housset M; Durdux C; Taieb J; Berger A; Coriat R; Chaussade S; Dousset B; Nordlinger B; Burgun A
Sci Rep; 2018 Aug; 8(1):12611. PubMed ID: 30135549
[TBL] [Abstract][Full Text] [Related]
59. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
